Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01506609 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 294
- Enrollment target
NCT01506609 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 294 participants.
The verdict
NCT01506609, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 294 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the progression-free survival (PFS) of oral veliparib in combination with TMZ or in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in subjects with BRCA1 or BRCA2 mutation and locally recurrent or metastatic breast cancer.
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Paclitaxel
- DRUG Temozolomide
- DRUG Veliparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2012-01-23 |
| Est. Completion | 2020-09-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01506609
The ClinicalTrials.gov registry entry for NCT01506609 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT01506609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01506609 about?
NCT01506609 is a clinical study titled "Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer". The primary objective of the study is to assess the progression-free survival (PFS) of oral veliparib in combination with TMZ or in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in subjects with BRCA1 or BRCA2 mutation and locally recurrent or metast...
What is the current status of trial NCT01506609?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 294 participants. The study started on 2012-01-23. Estimated completion is 2020-09-02.
What interventions are being tested in trial NCT01506609?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Paclitaxel (DRUG), Temozolomide (DRUG), Veliparib (DRUG).
Who is sponsoring clinical trial NCT01506609?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.